Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Changji'an Capsule is a Traditional Chinese Medicine (TCM) formulation developed by The First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is primarily investigated for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D), specifically targeting the "Liver Qi invading Spleen" syndrome (Gan Yu Cheng Pi). The formulation is designed to harmonize the liver and spleen, a common therapeutic approach in TCM for gastrointestinal disorders characterized by abdominal pain and altered bowel habits. Clinical evaluation has focused on its efficacy in reducing abdominal pain and improving stool consistency in IBS-D patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Changji'an Capsule.